Annual EBITDA
-$217.67 M
-$54.79 M-33.64%
31 December 2023
Summary:
Verve Therapeutics annual earnings before interest, taxes, depreciation & amortization is currently -$217.67 million, with the most recent change of -$54.79 million (-33.64%) on 31 December 2023. During the last 3 years, it has fallen by -$178.37 million (-453.88%). VERV annual EBITDA is now -1508.07% below its all-time high of -$13.54 million, reached on 31 December 2019.VERV EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$55.16 M
+$2.02 M+3.53%
30 September 2024
Summary:
Verve Therapeutics quarterly earnings before interest, taxes, depreciation & amortization is currently -$55.16 million, with the most recent change of +$2.02 million (+3.53%) on 30 September 2024. Over the past year, it has dropped by -$4.30 million (-8.45%). VERV quarterly EBITDA is now -761.81% below its all-time high of -$6.40 million, reached on 30 June 2020.VERV Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$219.97 M
-$4.30 M-1.99%
30 September 2024
Summary:
Verve Therapeutics TTM earnings before interest, taxes, depreciation & amortization is currently -$219.97 million, with the most recent change of -$4.30 million (-1.99%) on 30 September 2024. Over the past year, it has dropped by -$7.95 million (-3.75%). VERV TTM EBITDA is now -2953.46% below its all-time high of -$7.20 million, reached on 31 March 2020.VERV TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
VERV EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -33.6% | -8.4% | -3.8% |
| 3 y3 years | -453.9% | -138.9% | -210.7% |
| 5 y5 years | - | - | - |
VERV EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -453.9% | at low | -138.9% | +3.6% | -210.7% | at low |
| 5 y | 5 years | -1508.1% | at low | -761.8% | +3.6% | -2953.5% | at low |
| alltime | all time | -1508.1% | at low | -761.8% | +3.6% | -2953.5% | at low |
Verve Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$55.16 M(-3.5%) | -$219.97 M(+2.0%) |
| June 2024 | - | -$57.17 M(+3.5%) | -$215.68 M(-0.0%) |
| Mar 2024 | - | -$55.21 M(+5.3%) | -$215.75 M(-0.9%) |
| Dec 2023 | -$217.67 M(+33.6%) | -$52.43 M(+3.1%) | -$217.67 M(+2.7%) |
| Sept 2023 | - | -$50.86 M(-11.2%) | -$212.02 M(+3.8%) |
| June 2023 | - | -$57.25 M(+0.2%) | -$204.31 M(+8.3%) |
| Mar 2023 | - | -$57.13 M(+22.1%) | -$188.60 M(+15.8%) |
| Dec 2022 | -$162.88 M | -$46.78 M(+8.4%) | -$162.88 M(+9.9%) |
| Sept 2022 | - | -$43.14 M(+3.8%) | -$148.17 M(+15.7%) |
| June 2022 | - | -$41.54 M(+32.3%) | -$128.11 M(+24.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$31.41 M(-2.0%) | -$103.18 M(+20.6%) |
| Dec 2021 | -$85.53 M(+117.6%) | -$32.07 M(+38.9%) | -$85.53 M(+20.8%) |
| Sept 2021 | - | -$23.09 M(+39.0%) | -$70.81 M(+26.3%) |
| June 2021 | - | -$16.61 M(+20.6%) | -$56.07 M(+22.3%) |
| Mar 2021 | - | -$13.77 M(-20.6%) | -$45.86 M(+16.7%) |
| Dec 2020 | -$39.30 M(+190.3%) | - | - |
| Dec 2020 | - | -$17.35 M(+107.8%) | -$39.30 M(+79.0%) |
| Sept 2020 | - | -$8.35 M(+30.4%) | -$21.95 M(+61.4%) |
| June 2020 | - | -$6.40 M(-11.2%) | -$13.60 M(+88.8%) |
| Mar 2020 | - | -$7.20 M | -$7.20 M |
| Dec 2019 | -$13.54 M | - | - |
FAQ
- What is Verve Therapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Verve Therapeutics?
- What is Verve Therapeutics annual EBITDA year-on-year change?
- What is Verve Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Verve Therapeutics?
- What is Verve Therapeutics quarterly EBITDA year-on-year change?
- What is Verve Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Verve Therapeutics?
- What is Verve Therapeutics TTM EBITDA year-on-year change?
What is Verve Therapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of VERV is -$217.67 M
What is the all time high annual EBITDA for Verve Therapeutics?
Verve Therapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is -$13.54 M
What is Verve Therapeutics annual EBITDA year-on-year change?
Over the past year, VERV annual earnings before interest, taxes, depreciation & amortization has changed by -$54.79 M (-33.64%)
What is Verve Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of VERV is -$55.16 M
What is the all time high quarterly EBITDA for Verve Therapeutics?
Verve Therapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is -$6.40 M
What is Verve Therapeutics quarterly EBITDA year-on-year change?
Over the past year, VERV quarterly earnings before interest, taxes, depreciation & amortization has changed by -$4.30 M (-8.45%)
What is Verve Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of VERV is -$219.97 M
What is the all time high TTM EBITDA for Verve Therapeutics?
Verve Therapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is -$7.20 M
What is Verve Therapeutics TTM EBITDA year-on-year change?
Over the past year, VERV TTM earnings before interest, taxes, depreciation & amortization has changed by -$7.95 M (-3.75%)